AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2998802 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30863852 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of AmB and 5FC
Number of subjects: 0
Study 30863852 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of oral FLU and 5FC
Number of subjects: 0
Study 30863852 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of AmB and 5FC
Number of subjects: 0
Study 30863852 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of AmB and FLU
Number of subjects: 0
Study 30863852 — intervention group
Group type: COMPARATOR
Intervention: 1 week of AmB and FLU
Number of subjects: 0
Study 30863852 — intervention group
Group type: COMPARATOR
Intervention: 2 weeks of oral 5FC and FLU
Number of subjects: 0
Study 28992261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of measles vaccine (MV) at 4.5 and 9 months of age
Number of subjects: 5626
Study 28992261 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of measles vaccine (MV) at 9 months of age
Number of subjects: 5626
Study 26576710 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (200 μg/kg intravenous, 20 mg intravenous, 20 mg subcutaneous)
Number of subjects: 208
Study 26576710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 25318924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 696
Study 25318924 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 696
Study 23019947 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogenase for injection + Sanmiao Powder (SP) administration
Number of subjects: 80
Study 23019947 — intervention group
Group type: COMPARATOR
Intervention: Fibrinogenase for injection alone
Number of subjects: 80
Study 20573755 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise- or diet-induced weight loss intervention
Number of subjects: 106
Study 17943541 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17beta-estradiol daily plus 10 mg dydrogesterone for 14 days of each 28-day cycle (n = 44)
Number of subjects: 80
Study 17943541 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 36)
Number of subjects: 80
Study 16230985 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (150 mg daily)
Number of subjects: 6
Study 16230985 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (150 mg) plus vitamin E (1,000 IU daily)
Number of subjects: 6
Study 16230985 — intervention group
Group type: COMPARATOR
Intervention: Placebo run-in
Number of subjects: 6
Study 16230985 — intervention group
Group type: COMPARATOR
Intervention: Placebo wash-out
Number of subjects: 6
Study 11717654 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous combined hormone replacement therapy (0.3 mg conjugated equine estrogens and 2.5 mg medroxyprogesterone acetate plus 1000 mg calcium per day)
Number of subjects: 60
Study 11717654 — intervention group
Group type: COMPARATOR
Intervention: Control group (1000 mg calcium per day alone)
Number of subjects: 60
Study 9138278 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2a 3 MU three times weekly for 22 weeks
Number of subjects: 88
Study 9138278 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha‐2a 6 MU three times weekly for 22 weeks
Number of subjects: 88
Study 9138278 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN therapy (both dosages)
Number of subjects: 88
Study 7950032 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Management Protocol (CAMP)
Number of subjects: 58
Study 7950032 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 58
Study 3066430 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal training
Number of subjects: 20
Study 3066430 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 20
Study 2195426 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 administration
Number of subjects: 0
Study 2195426 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 administration
Number of subjects: 0
Study 2195426 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 966243 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 200 (T Cu 200)
Number of subjects: 0
Study 966243 — intervention group
Group type: COMPARATOR
Intervention: Dalkon shield
Number of subjects: 0
Study 30357360 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly haemodialysis (2×HD)
Number of subjects: 565
Study 30357360 — intervention group
Group type: COMPARATOR
Intervention: Thrice-weekly haemodialysis (3×HD)
Number of subjects: 565
Study 28296003 — intervention group
Group type: EXPERIMENTAL
Intervention: Celt ACD®
Number of subjects: 207
Study 28296003 — intervention group
Group type: COMPARATOR
Intervention: Manual Compression (MC)
Number of subjects: 207
Study 26006264 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Remediation Therapy (CRT)
Number of subjects: 130
Study 26006264 — intervention group
Group type: COMPARATOR
Intervention: Active Computerized Control (CC)
Number of subjects: 130
Study 26006264 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 130
Study 23370155 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine
Number of subjects: 801
Study 23370155 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical circumcision
Number of subjects: 801
Study 23370155 — intervention group
Group type: COMPARATOR
Intervention: Vaccine recipients
Number of subjects: 801
Study 21997650 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein harvesting (EVH)
Number of subjects: 40
Study 21997650 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting (OVH)
Number of subjects: 40
Study 19858156 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard parenteral nutrition solution
Number of subjects: 59
Study 19858156 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum exposure above the median (55 microg/kg)
Number of subjects: 59
Study 19858156 — intervention group
Group type: COMPARATOR
Intervention: Aluminum-depleted parenteral nutrition solutions
Number of subjects: 59
Study 17074322 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ovarian age-based stimulation with microdose GnRH agonist (GnRH-a) and 450-600 IU of gonadotropin daily.
Number of subjects: 62
Study 17074322 — intervention group
Group type: COMPARATOR
Intervention: Standard chronological age-based stimulation with long luteal phase GnRH-a and up to 300 IU of gonadotropins.
Number of subjects: 62
Study 17074322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups achieved a 47% rate of first positive pregnancy test (hCG).
Number of subjects: 62
Study 16010101 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser myringotomy
Number of subjects: 25
Study 16010101 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy and ventilation tube (VT) insertion
Number of subjects: 25
Study 11717641 — intervention group
Group type: EXPERIMENTAL
Intervention: McDonald cerclage
Number of subjects: 113
Study 11717641 — intervention group
Group type: COMPARATOR
Intervention: No cerclage
Number of subjects: 113
Study 11717641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 113
Study 9233079 — intervention group
Group type: EXPERIMENTAL
Intervention: Training workshop for selected members to spread knowledge and skills of oral rehydration therapy.
Number of subjects: 0
Study 8123269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 0.1 mEq/ml of sodium bicarbonate (NaHCO3)
Number of subjects: 184
Study 8123269 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine alone
Number of subjects: 184
Study 2888018 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units)
Number of subjects: 219
Study 2888018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 29851791 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TB therapy with isoniazid, rifampicin, ethambutol, and pyrazinamide for 6 months
Number of subjects: 1
Study 27678430 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TA-8995
Number of subjects: 187
Study 27678430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study 26618177 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope (McL)
Number of subjects: 17
Study 26618177 — intervention group
Group type: COMPARATOR
Intervention: Pentax‐AWS Airwayscope (AWS)
Number of subjects: 17
Study 26618177 — intervention group
Group type: EXPERIMENTAL
Intervention: McGRATH MAC (McGRATH)
Number of subjects: 17
Study 23437399 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory and Clinical Monitoring (LCM, 12-weekly CD4s)
Number of subjects: 3316
Study 23437399 — intervention group
Group type: COMPARATOR
Intervention: Clinically-Driven Monitoring (CDM, CD4s measured but blinded)
Number of subjects: 3316
Study 20884430 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V(r) everolimus‐eluting stent (EES)
Number of subjects: 154
Study 20884430 — intervention group
Group type: COMPARATOR
Intervention: TAXUS Express2(tm) paclitaxel-eluting stent (PES)
Number of subjects: 154
Study 18226762 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17009166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified whole milk
Number of subjects: 19
Study 17009166 — intervention group
Group type: COMPARATOR
Intervention: Unfortified whole milk
Number of subjects: 19
Study 17009166 — intervention group
Group type: COMPARATOR
Intervention: Fortified skimmed milk
Number of subjects: 19
Study 17009166 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of milk (fortified whole, unfortified whole, and fortified skimmed)
Number of subjects: 19
Study 12728487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 0.3 ml (15 micrograms) added to 0.5% hyperbaric bupivacaine 2.0 ml
Number of subjects: 24
Study 12728487 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline 0.3 ml added to 0.5% hyperbaric bupivacaine 2.0 ml
Number of subjects: 24
Study 11483142 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive enhancement therapy (NET) plus work therapy (WT)
Number of subjects: 65
Study 11483142 — intervention group
Group type: COMPARATOR
Intervention: Work therapy (WT) alone
Number of subjects: 65
Study 9404379 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl + voluntary cough (Control)
Number of subjects: 10
Study 9404379 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0% NaCl
Number of subjects: 10
Study 9404379 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0% NaCl
Number of subjects: 10
Study 9404379 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% NaCl
Number of subjects: 10
Study 8314291 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g cefuroxime i.v. at induction of anaesthesia (prophylaxis group)
Number of subjects: 200
Study 8314291 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics perioperatively (control group)
Number of subjects: 200
Study 3111238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide
Number of subjects: 29
Study 3111238 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 29
Study 31501920 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater height (HR per 10 cm)
Number of subjects: 2500
Study 31501920 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg length
Number of subjects: 2500
Study 31501920 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for liver fat and triacylglycerols, adiponectin and C-reactive protein
Number of subjects: 2500
Study 28832288 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory screening prior to ART
Number of subjects: 771
Study 26056838 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB with catheter at level Th 4, 10 ml each of 1:2 mixture of bupivacaine 0.5% and lidocaine 2% with adrenaline injected at three different levels
Number of subjects: 70
Study 26056838 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA) with sevoflurane
Number of subjects: 70
Study 26056838 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB with catheter
Number of subjects: 70
Study 26056838 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 70
Study 26056838 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB with catheter and GA
Number of subjects: 70
Study 23165913 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol treatment
Number of subjects: 94
Study 21639927 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus cooling (target rectal temperature of 33-34°C for 72 hrs, started within 3 h of birth)
Number of subjects: 36
Study 21639927 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 36
Study 21639927 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus cooling
Number of subjects: 36
Study 19901110 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (arm A)
Number of subjects: 318
Study 19901110 — intervention group
Group type: COMPARATOR
Intervention: Procarbazine, lomustine (CCNU), and vincristine (PCV; arm B1)
Number of subjects: 318
Study 19901110 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (arm B2)
Number of subjects: 318
Study 19901110 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermethylation of the MGMT promoter
Number of subjects: 318
Study 19901110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations of the isocitrate dehydrogenase (IDH1) gene
Number of subjects: 318
Study 19901110 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligodendroglial histology
Number of subjects: 318
Study 16546486 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE margarine (3 g)
Number of subjects: 26
Study 16546486 — intervention group
Group type: COMPARATOR
Intervention: Placebo margarine (0 g)
Number of subjects: 26
Study 16546486 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (400 kcal, 5 d/wk at 65% of VO2 reserve)
Number of subjects: 26
Study 12775317 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using topical methyl aminolevulinate (Metvix)
Number of subjects: 204
Study 12775317 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 204
Study 12775317 — intervention group
Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 204
Study 11236176 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal approach
Number of subjects: 120
Study 11236176 — intervention group
Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 120
Study 8968971 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (n = 22)
Number of subjects: 71
Study 8968971 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy (n = 24)
Number of subjects: 71
Study 8968971 — intervention group
Group type: COMPARATOR
Intervention: Cervical collars (n = 25)
Number of subjects: 71
Study 1533329 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar iEMG during isotonic exercise (60% of maximum isometric torque)
Number of subjects: 28
Study 1533329 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exertion
Number of subjects: 28
Study 1533329 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric exertion
Number of subjects: 28
Study 1533329 — intervention group
Group type: COMPARATOR
Intervention: iEMG fatigue slopes
Number of subjects: 28
Study 6152058 — intervention group
Group type: EXPERIMENTAL
Intervention: RS 86, 0.5-4 mg orally
Number of subjects: 10
Study 6152058 — intervention group
Group type: EXPERIMENTAL
Intervention: RS 86, 4 mg orally
Number of subjects: 10
Study 6152058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30073931 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg/day for one week after each doxorubicin dose
Number of subjects: 80
Study 30073931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 30073931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Silymarin and Placebo)
Number of subjects: 80
Study 30089301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (7 days, 1,500 mg/day)
Number of subjects: 40
Study 30089301 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (7 days, 1,500 mg/day)
Number of subjects: 40
Study 30089301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30089301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin and Amoxicillin
Number of subjects: 40
Study 27456342 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week free nicotine replacement therapy (NRT) sample and medication counselling
Number of subjects: 0
Study 27456342 — intervention group
Group type: COMPARATOR
Intervention: Advice to purchase NRT on their own
Number of subjects: 0
Study 24313236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake cotinine
Number of subjects: 103
Study 24313236 — intervention group
Group type: EXPERIMENTAL
Intervention: Years smoked (self-report metric)
Number of subjects: 103
Study 23477217 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic enzyme therapy in combination with antibiotics
Number of subjects: 0
Study 23477217 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 0
Study 20591872 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrified oocytes
Number of subjects: 600
Study 20591872 — intervention group
Group type: COMPARATOR
Intervention: Fresh oocytes
Number of subjects: 600
Study 17384344 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fat-rich diet (MUFA)
Number of subjects: 11
Study 17384344 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich diet (CHO)
Number of subjects: 11
Study 17384344 — intervention group
Group type: COMPARATOR
Intervention: Saturated fat diet (SAT)
Number of subjects: 11
Study 16304298 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration (MUF)
Number of subjects: 40
Study 16304298 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration (CUF)
Number of subjects: 40
Study 12230061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraabdominal passive gas drain left for four hours postoperatively
Number of subjects: 80
Study 12230061 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no gas drain)
Number of subjects: 80
Study 10470844 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen with CCNU, cyclophosphamide, adriamycin (CCA) and VP16
Number of subjects: 394
Study 10470844 — intervention group
Group type: COMPARATOR
Intervention: Alternating regimen (CCA regimen alternating with cisplatin‐vindesine‐VP16)
Number of subjects: 394
Study 10470844 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited SCLC patients (Standard regimen)
Number of subjects: 394
Study 10470844 — intervention group
Group type: COMPARATOR
Intervention: Limited SCLC patients (Alternating regimen)
Number of subjects: 394
Study 10470844 — intervention group
Group type: COMPARATOR
Intervention: Alternating regimen
Number of subjects: 394
Study 9360863 — intervention group
Group type: EXPERIMENTAL
Intervention: Random presentation order of stimulus level
Number of subjects: 40
Study 9360863 — intervention group
Group type: COMPARATOR
Intervention: Sequential presentation order of stimulus level
Number of subjects: 40
Study 9360863 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level referent presented at the start of each trial
Number of subjects: 40
Study 9360863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending runs in sequential presentation
Number of subjects: 40
Study 9360863 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending runs in sequential presentation
Number of subjects: 40
Study 2030596 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Anna Pavala Sindhooram (APSm)
Number of subjects: 30
Study 2030596 — intervention group
Group type: COMPARATOR
Intervention: withdrawal of APSm
Number of subjects: 30
Study 7125153 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (topical steroid), 1-week pretreatment before nasal histamine challenge
Number of subjects: 0
Study 7125153 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 1-week pretreatment before nasal histamine challenge
Number of subjects: 0
Study 30467056 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine+mometasone furoate
Number of subjects: 108
Study 30467056 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine+mometasone furoate+montelukast
Number of subjects: 108
Study 30467056 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast+mometasone furoate
Number of subjects: 108
Study 30467056 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast+mometasone furoate+loratadine
Number of subjects: 108
Study 31542275 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon guide catheter (BGC)
Number of subjects: 887
Study 31542275 — intervention group
Group type: COMPARATOR
Intervention: No balloon guide catheter (BGC)
Number of subjects: 887
Study 29074595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 110
Study 29074595 — intervention group
Group type: COMPARATOR
Intervention: Best Available Therapy (BAT)
Number of subjects: 110
Study 26365936 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotyping group (VerifyNow P2Y12 assay)
Number of subjects: 0
Study 26365936 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping group (CYP2C19 *2 allele testing)
Number of subjects: 0
Study 26365936 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard-dose clopidogrel)
Number of subjects: 0
Study 26365936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24060143 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine (PI) group (Gr I)
Number of subjects: 55
Study 24060143 — intervention group
Group type: COMPARATOR
Intervention: Non-povidone iodine (non-PI) group (Gr II)
Number of subjects: 55
Study 22690673 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Body Weight (TBW) for propofol clearance
Number of subjects: 20
Study 22690673 — intervention group
Group type: EXPERIMENTAL
Intervention: Central volume of distribution
Number of subjects: 20
Study 22690673 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral volume
Number of subjects: 20
Study 22690673 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercompartmental clearance
Number of subjects: 20